314069-33-5

Upstream product

• 13076-19-2 (3R,6S)-3,6-dimethyl-1,4-dioxane-2,5-dione 
• 100-51-6 benzyl alcohol 
• 4511-42-6 L,L-dilactide 
• 100-39-0 benzyl bromide 
• 923-17-1 (S,S)-2-[(2-hydroxypropanoyl)oxy]propanoic acid 
• 1020280-84-5 O-t-butyllactic acid dimer benzyl ester 

Downstream Products

• 1020280-87-8 O-t-butyllactic acid tetramer benzyl ester 
• 909025-02-1 C₂₂H₃₄O₇Si 
• 909025-03-2 C₂₅H₃₈O₉Si 
• 909025-06-5 C₂₈H₄₂O₁₁Si 
• 909025-08-7 C₃₄H₅₀O₁₅Si 
• 909025-07-6 C₃₁H₄₆O₁₃Si 
• 909025-11-2 (2S)-1-{[(2S)-1-{[(2S)-1-{[(2S)-1-{[(2S)-1-(benzyloxy)-1-oxopropan-2-yl]oxy}-1-oxopropan-2-yl]oxy}-1-oxopropan-2-yl]oxy}-1-oxopropan-2-yl]oxy}-1-oxopropan-2-yl (2S)-2-hydroxypropanoate 
• 1079277-94-3 C₁₉H₃₀O₅Si 
• 909025-05-4 (S)-2-hydroxypropionic acid (S)-1-[(S)-1-((S)-1-benzyloxycarbonylethoxycarbonyl)ethoxycarbonyl]ethyl ester 
• 1396314-82-1 C₃₇H₅₈O₁₃Si 
• 1396314-81-0 6-[(S)-2-((S)-2-hydroxypropanoyloxy)propanoate]hexanoic benzyl ester 

Relevant academic research and scientific papers

Thiourea-based bifunctional organocatalysis: Supramolecular recognition for living polymerization

A versatile, metal-free, organocatalytic approach to the living ring-opening polymerization of lactide using a bifunctional thiourea-tertiary amine catalyst is described. Mild and highly selective polymerization conditions produced poly(lactides) with predictable molecular weights and extremely narrow polydispersities (～ 1.05), characteristic of a living polymerization. The extraordinary selectivity of this catalyst system for polymerization relative to transesterification is remarkably unusual. The low polydispersities and exceptional control observed are a consequence of selective transesterification of lactide relative to the open chain esters. Presumably, the ring strain of lactide provides both a driving force for the polymerization and a kinetic preference for polymerization relative to transesterification with catalyst. We postulate that the initiating/propagating alcohol is activated by acid-base interaction with the tertiary amine moiety and the carbonyl of the lactide monomer is simultaneously activated by hydrogen bonding to the thiourea moiety of the catalyst. Copyright

Crystallization Induced Self-Assembly: A Strategy to Achieve Ultra-Small Domain Sizes

Achieving self-assembled nanostructures with ultra-small feature sizes (e. g., below 5 nm) is an important prerequisite for the development of block copolymer lithography. In this work, the preparation and self-assembly of a series of giant molecules composed of vinyl polyhedral oligomeric silsesquioxane (VPOSS) tethered with monodispersed oligo(L-lactide) chains are presented. Small-angle X-ray scattering (SAXS) and transmission electron microscopy (TEM) results demonstrate that ultra-small domain sizes (down to 3 nm) of phase separated lamellar morphology are achieved in bulk, driven by the strong tendency and fast kinetics for crystallization of VPOSS moieties. Moreover, upon gamma ray radiation, VPOSS cages in the lamellar structure can be crosslinked via polymerization of the vinyl groups. After pyrolysis at high temperature, ultra-thin two-dimensional nano-silica sheets can be obtained.

DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY

New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a microparticle in vivo, wherein the timolol prodrug containing microparticle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.

DRUGS TO TREAT OCULAR DISORDERS

The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Hydrophilic Oligo(lactic acid)s Captured by a Hydrophobic Polyaromatic Cavity in Water

Biologically relevant hydrophilic molecules rarely interact with hydrophobic compounds and surfaces in water owing to effective hydration. Nevertheless, herein we report that the hydrophobic cavity of a polyaromatic capsule, formed through coordination-driven self-assembly, can encapsulate hydrophilic oligo(lactic acid)s in water with relatively high binding constants (up to Ka=3×105 m?1). X-ray crystallographic and ITC analyses revealed that the unusual host–guest behavior is caused by enthalpic stabilization through multiple CH–π and hydrogen-bonding interactions. The polyaromatic cavity stabilizes hydrolyzable cyclic di(lactic acid) and captures tetra(lactic acid) preferentially from a mixture of oligo(lactic acid)s even in water.

DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS

The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Compounds And Compositions for the Treatment of Ocular Disorders

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Amplifying (Im)perfection: The Impact of Crystallinity in Discrete and Disperse Block Co-oligomers

Crystallinity is seldomly utilized as part of the microphase segregation process in ultralow-molecular-weight block copolymers. Here, we show the preparation of two types of discrete, semicrystalline block co-oligomers, comprising an amorphous oligodimethylsiloxane block and a crystalline oligo-l-lactic acid or oligomethylene block. The self-assembly of these discrete materials results in lamellar structures with unforeseen uniformity in the domain spacing. A systematic introduction of dispersity reveals the extreme sensitivity of the microphase segregation process toward chain length dispersity in the crystalline block.

Unique cation binding capability of cyclic oligo(l-lactic acid) (l-COLA)

Cyclic l-lactic acid octamer (l-COLA-8) shows a unique complexing capability towards alkali and alkali earth metal cations in acetonitrile-d3/chloroform-d (9/1). The valence of the cation affects the stoichiometry of the complexes between l-COLA-8 and the cation; l-COLA-8 forms a 2:1 complex with alkali metal cations, but forms a 1:1 complex with alkali earth metal cations. Additionally, l-COLA-8 shows a binding selectivity for Rb+ and Ba2+, which have a diameter about 3 ?.

Synthesis and characterization of well-defined l-lactic acid-caprolactone co-oligomers and their rhenium (I) and technetium(I) conjugates

Staring from l-lactide and ε-caprolactone, the corresponding lactic-caprolactone cooligomer with hydroxyl and carboxylic acid groups were synthesized. These oligomers were connected with chelating groups through a long chain tether, ready for transition metal binding. Coordination of organometallic rhenium(I) and technetium(I) complexes generated the conjugates in high yield and short time, satisfying the requirements for short-lived radiopharmaceuticals in clinical applications. A reasonable pharmacophore model has been established to guide the design of well-defined lactic acid oligomer for nuclear medicine.